Enovis (ENOV) Expected to Release Earnings on Thursday

Enovis (NYSE:ENOV) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Enovis to post earnings of $0.8470 per share and revenue of $581.8370 million for the quarter. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 EPS. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Price Performance

NYSE:ENOV opened at $31.42 on Tuesday. Enovis has a 52-week low of $19.14 and a 52-week high of $34.28. The company has a market cap of $1.81 billion, a P/E ratio of -1.58 and a beta of 1.34. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock’s 50-day simple moving average is $24.20 and its 200 day simple moving average is $23.85.

Insider Transactions at Enovis

In other Enovis news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the purchase, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased a total of 4,200 shares of company stock valued at $92,084 in the last 90 days. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enovis

A number of large investors have recently added to or reduced their stakes in ENOV. Arax Advisory Partners bought a new position in Enovis during the fourth quarter worth $29,000. EverSource Wealth Advisors LLC raised its position in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Danske Bank A S acquired a new stake in shares of Enovis during the 3rd quarter worth about $64,000. iSAM Funds UK Ltd acquired a new stake in shares of Enovis during the 3rd quarter worth about $80,000. Finally, Brown Brothers Harriman & Co. bought a new stake in shares of Enovis during the 3rd quarter worth about $90,000. Institutional investors own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

ENOV has been the topic of several recent analyst reports. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. William Blair initiated coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating on the stock. Finally, Evercore set a $32.00 price target on shares of Enovis in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $41.86.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.